Plus Therapeutics (PSTV) said Thursday that its Rhenium obisbemeda radiotherapy has been granted orphan drug designation by the US Food and Drug Administration for treating leptomeningeal metastases in lung cancer patients.
The company said the designation follows the completion of its phase 1 single-dose trial, which established the recommended Phase 2 dose. Plus Therapeutics is advancing a Phase 2 single-dose expansion trial and a Phase 1 multiple-dose trial.
Shares of Plus Therapeutics surged past 36% in recent Thursday trading.
Price: 0.48, Change: +0.13, Percent Change: +36.57
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。